A clinical trial to investigate the intravenous formulation of brincidofovir for the prevention and treatment of cytomegalovirus (CMV) and BK virus in haematopoietic cell transplants (HCT) and kidney transplant recipients

Trial Profile

A clinical trial to investigate the intravenous formulation of brincidofovir for the prevention and treatment of cytomegalovirus (CMV) and BK virus in haematopoietic cell transplants (HCT) and kidney transplant recipients

Planning
Phase of Trial: Phase I

Latest Information Update: 08 Aug 2016

At a glance

  • Drugs Brincidofovir (Primary)
  • Indications Cytomegalovirus infections; Polyomavirus infections
  • Focus Adverse reactions; First in man
  • Most Recent Events

    • 08 Aug 2016 According to a Chimerix media release, this trail is expected initiate in the second half of 2016.
    • 16 May 2016 New trial record
    • 09 May 2016 An IND application for the intravenous (IV) formulation of brincidofovir is anticipated to be filed with the FDA in the third quarter of 2016, according to a Chimerix media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top